Evidence Based Data


GcMAF is a vitamin D-binding protein. The name GcMAF is short for Glycoprotein Macrophage Activating Factor and is what is scientifically referred to as a GC-protein.
Let’s simplify:

  • A GC-protein is a kind of protein that binds itself to vitamin D (which occurs naturally in the body,) and in turn, it triggers macrophages to fight against cancer cells and other diseases threatening the body.
  • Macrophages are important immune system cells that are formed in response to an infection or when damaged or dead cells accumulate in the body. 


GcMAF and Cancer



When a body has cancer, cancer cells and tumors release a protein called nagalase. When nagalase is released, it prevents immune system cells from functioning properly, allowing cancer to grow without interruption.
Because of this, your natural GcMAF protein production is blocked from initiating an immune response.
When the body lacks GcMAF, it weakens and prevents the immune system from working properly. When a body has enough GcMAF, it jump-starts the entire immune response.
When a patient receives GcMAF as a treatment, the proteins trigger the body’s natural fighting cells, (the macrophages mentioned above,) and support and rebuild the immune system. This helps destroy cancerous cells or any other foreign invader in the body.

GcMAF is a type of immunotherapy, which is a method that helps boost the body’s immune system to fight diseases. A study in 2017 looked at how GcMAF could block things that weaken the immune system, like the nagalase enzyme. This treatment was found to be good at making immune cells more active in fighting tumor cells. The study showed that GcMAF works faster and better in treating certain types of tumor cells, like breast and prostate cancer cells, compared to other kinds like squamous carcinoma cells.

Learn more here:


How is it Administered?


A dose of active GcMAF is injected intramuscularly or subcutaneously once a week for a period of 10 weeks. The treatment can be done at home or in specialized alternative clinics.

The injections activate the immune system to attack cancer cells.
In certain cases, a doctor will recommend that a patient receive GcMAF either intravenously or through a nebulizer.
After 10 weeks, additional doses may be required depending on the stage and type of disease and based on disease symptoms, pathology, and progress of improvement. Treatment should be continued as long as necessary while the disease is present.

We strongly believe that having a professional integrative nurse/doctor as an online counselor can greatly benefit your healing with GcMAF.


How Effective is GcMAF in the Fight Against Cancer?


In recent decades, scientific research on GcMAF treatments has shown it to be a highly effective measure in fighting against a variety of cancers.

When patients receive GcMAF, and there is a sufficient amount of macrophages produced in the body, the immune system is able to pursue cancerous cells aggressively enough to lead to remission.

Three studies published by internationally recognized research immunologist and molecular biologist, Nobuto Yamamoto, Ph.D., have shown that incredibly small weekly doses (100 billionths of a gram – an amount invisible to the naked eye) of GcMAF cured early metastatic breast, prostate, and colon cancers in 100% of (nonanemic) patients. In a fourth study, he used the same treatment to cure 100% of nonanemic HIV-infected patients.


Side effects of GcMAF therapy

A 2002 article about GcMAF published by the Journal of the National Cancer InstituteTr states that mice and humans who were given purified GcMAF had no side effects.


What Diseases Is It Used For? 

In addition to cancer, it is used to treat diseases such as Hepatitis B and C, Herpes, Endometriosis, Autism Spectrum Disorders, Lyme disease, Chronic Fatigue Syndrome, Fibromyalgia, Endometriosis, Psoriasis, Malaria, Lupus, Osteoporosis, Type 1 Diabetes COVID 19.

Teri explains how GcMAFplus helped her ongoing over many years.
The Wonders Of Gcmaf And What It Can Do For Your Health
Corina explains of GcMAFplus helped her immune system issues.

GcMAF- Relevant Research and News

Vitamin D Binding Protein-Macrophage Activating Factor Inhibits HCC in SCID Mice

Background: A high incidence of recurrence after treatment is the most serious problem in hepatocellular carcinoma (HCC). Therefore, a new strategy for the treatment of the disease is needed. The aim of the present study was to investigate whether vitamin D binding protein-macrophage activating factor (DBP-maf) is able to inhibit the growth of HCC.

Methods: The effects of DBP-maf on endothelial cells and macrophage were evaluated by WST-1 assay and phagocytosis assay, respectively. Human HCC cells (HepG2) were implanted into the dorsum of severe combined immunodeficiency (SCID) mice. These mice were divided into control and DBP-maf treatment groups (n = 10/group). The mice in the treatment group received 40 ng/kg/d of DBP-maf for 21 d.
Results: DBP-maf showed anti-proliferative activity against endothelial cells and also activated phagocytosis by macrophages. DBP-maf inhibited the growth of HCC cells (treatment group: 126 ± 18mm(3), untreated group: 1691.5 ± 546.9mm(3), P = 0.0077). Histologic examinations of the tumors revealed the microvessel density was reduced and more macrophage infiltration was demonstrated in the tumor of mice in the treatment group.
Conclusion: DBP-maf has at least two novel functions, namely, an anti-angiogenic activity and tumor killing activity through the activation of macrophages. DBP-maf may therefore represent a new strategy for the treatment of HCC.

Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy

Background: Gc protein-derived macrophageactivating factor (GcMAF) occurs naturally in the human body.
It has various functions, such as macrophage activation and antitumor activities. Recently, immunotherapy has become an attractive new strategy in the treatment of cancer.

GcMAF-based immunotherapy can be combined with many other therapies. Sonodynamic therapy (SDT) using low-intensity ultrasound is a novel therapeutic modality. Ultrasound has been demonstrated to activate a number of sonosensitive agents allowing for the possibility of non-invasive targeted treatment for both superficial and deep-seated tumors.

The current case study demonstrates that GcMAF and SDT can be used in combination with conventional therapies in patients with metastatic cancer, especially where treatment options are limited due to factors such as toxicity. This case study also suggests a new concept of cancer treatment using local destruction of cancer tissue, in this case conducted with SDT, to be used in combination with GcMAF immunotherapy as a systemic treatment.
Immunotherapy has become an attractive new strategy in the treatment of cancer, due in part to minimal toxicity and an excellent safety profile when compared to conventional therapies such as chemotherapy and radiation.

You might also be interested in


PEMF Therapy

Pulsed electromagnetic field (PEMF) therapy is an alternative treatment that may be beneficial in slowing cancer growth and helping patients with pain management.  So far, studies on PEMF and cancer in humans are

Read More »


What is Rituximab?   Rituximab, often known as Rituxan, is a monoclonal antibody fighting cancer. It is a cancer treatment that works by signaling cancer cells to die. It does that

Read More »
Budwig Protocol for Cancer

Budwig Protocol

What is Budwig?   The Budwig protocol is an anticancer diet that was invented by Dr. Johanna Budwig in the 1950s. Dr. Budwig was a German biochemist and pharmacist with a

Read More »

Interested in GcMAF but not sure how to start?

We can help!

Interested in GcMAF but not sure how to start? We can help

We’ll connect you with a specialist within 24 hours

Looking for alternative cancer treatments?

Our advisors have helped hundreds of patients navigate their alternative options.

This website uses cookies to ensure you get the best experience.